Dyadic International, Inc. (DYAI) AI Stock Analysis

Dyadic International, Inc., headquartered in Jupiter, Florida, operates as a pioneering biotechnology platform company focused on the development, production, and commercialization of enzymes and other proteins within the United States. Central to its operations is the utilization of its patented and proprietary C1 platform alongside other cutting-edge technologies. These enable Dyadic to conduct research, development, and commercial activities aimed at advancing human and animal vaccines as well as various drugs. Its product portfolio includes virus-like particles, antigens, monoclonal antibodies, and therapeutic proteins. Key initiatives include advancing its DYAI-100 SARS-CoV-2-RBD antigen vaccine candidate towards a Phase 1 clinical trial and collaborations with Syngene International Limited.

Dyadic saw revenue increase from $2.4M in FY2021 to $2.9M in FY2022 and $3.5M in FY2024, before falling 64.7% to $1.2M in FY2025. Gross margin contracted to -88.3% in FY2025 compared to 65.8% in FY2024. The company recorded continuous annual losses, reporting a net loss of -$13.1M in FY2021, -$9.7M in FY2022, -$6.8M in FY2023, -$5.8M in FY2024, and -$7.4M in FY2025. Operating cash flow was -$5.7M in FY2025 alongside R&D expenses of $2.2M. Over the 5-year period from FY2020 to FY2025, revenue compound annual growth rate stood at -5.1%. For the latest quarter ended June 30, 2026, quarterly revenue fell 0.6% year-over-year, bringing trailing twelve month revenue to $3.8M with an operating margin of -212.8%.

As of June 30, 2026, Dyadic reported $3.1M in cash and short-term investments and total debt of $5.0M, resulting in net debt of $1.9M. Total assets stood at $6.5M against shareholders' equity of -$2.4M, reflecting negative equity. The company maintained a current ratio of 1.65. Operating cash flow and free cash flow were both -$5.7M in FY2025. In terms of capital structure, the share count increased by 29.8% over the past 5 years.

Dyadic trades at a price-to-sales multiple of 4.3x, slightly above the 4.1x median of its US-listed Healthcare peers. Its forward P/E ratio is 15.8x compared to the peer median of 17.3x, while its enterprise value to revenue multiple is 13.9x. The stock has underperformed broader benchmarks, dropping 61.0% over the past 1 year and 91.5% over 5 years, compared to gains of 16.8% and 83.0% for the S&P 500 (SPY). As of October 16, 2026, the stock closed at $0.41, representing a 48.0% discount to its 200-day average.

Dyadic currently has 1 Strong Buy rating from analysts, with 0 Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $5.50, representing an upside of 1241.5% from the last close of $0.41. For the current fiscal year ending December 31, 2026, consensus expectations project revenue of $6.6M and an EPS estimate of -$0.14. For the next fiscal year, 3 analysts project revenue to reach $12.8M, representing 94.9% growth, with EPS estimated at $0.02. Over the last 4 quarters, the company recorded 0 EPS beats, and its next earnings date is November 11, 2026.

This page is an AI-written research summary of Dyadic International, Inc. (DYAI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: DYAI income statement, DYAI balance sheet, DYAI key metrics, DYAI analyst forecast, DYAI chart. See the DYAI stock overview for the latest quote and news.